Leading Pediatric Expert Supports Improvements in Child Health Products

A presentation published in a new volume of the Nestle Nutrition Workshop Series, “Protein and Energy Requirements in Infancy and Childhood” describes the health benefits of breast milk and also supports the addition of two recombinant human breast milk proteins to child health and nutrition products.

Sacramento, CA (PRWEB) October 24, 2006 -- A presentation published in a new volume of the Nestle Nutrition Workshop Series, “Protein and Energy Requirements in Infancy and Childhood” describes the health benefits of breast milk and also supports the addition of two recombinant human breast milk proteins to child health and nutrition products. The paper titled “Recombinant Human Milk Proteins” was presented by Bo Lönnerdal, Ph.D., Department of Nutrition, University of California, Davis at the 58th Nestle Nutrition Workshop, Pediatric Program, Ho Chi Minh City, Vietnam, November 2005.

This presentation emphasizes what numerous studies on breast milk have conclusively demonstrated – breast-fed infants have generally better health than formula-fed infants. Breast milk proteins “provide amino acids, but also facilitate the absorption of nutrients, stimulate growth and development of the intestine, modulate immune function and aid in the digestion of other nutrients,” said Dr. Lönnerdal.

Ventria Bioscience produces two recombinant breast milk proteins, Lactiva™ and Lysomin™ for use in medical foods and child health and nutrition products. Both of these proteins are found naturally in breast milk and have numerous beneficial effects for children who are breastfeeding. “Ventria’s Lactiva™ and Lysomin™ have been shown to have identical functional and biological activity as their breast milk counterparts,” said Dr. Lönnerdal. And because Ventria has discovered a method of making these proteins in an affordable system, the benefits of these proteins have the potential to help millions of children worldwide.

“Dr. Lönnerdal’s statements are consistent with a recently completed child health study which demonstrated that Ventria’s Lactiva and Lysomin, when added to standard oral rehydration solution, helped to reduce the duration of acute diarrhea in children by 30%, from 5.2 days to 3.7 days,” said Scott Deeter, President and CEO, Ventria Bioscience. “We are very pleased by the support from the pediatric medical community.”

For more information, see our website at Ventria Bioscience http://www.ventria.com

Or contact:
Brandy Sargent, Corporate Communications
(916) 921-6148 ext. 27

Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.

##
Contact Information
Brandy Sargent
Ventria Bioscience
http://www.ventria.com
916-921-6148 +27

Online Web 2.0 Version
You can read the online version of this press release here.